PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jbcThe Journal of Biological Chemistry
 
J Biol Chem. 2011 February 18; 286(7): 5657–5666.
Published online 2010 December 21. doi:  10.1074/jbc.M110.173039
PMCID: PMC3037679

The Cooperation of FGF Receptor and Klotho Is Involved in Excretory Canal Development and Regulation of Metabolic Homeostasis in Caenorhabditis elegans*An external file that holds a picture, illustration, etc.
Object name is sbox.jpg

Abstract

FGFs have traditionally been associated with cell proliferation, morphogenesis, and development; yet, a subfamily of FGFs (FGF19, -21, and -23) functions as hormones to regulate glucose, lipid, phosphate, and vitamin D metabolism with impact on energy balance and aging. In mammals, Klotho and beta-Klotho are type 1 transmembrane proteins that function as obligatory co-factors for endocrine FGFs to bind to their cognate FGF receptors (FGFRs). Mutations in Klotho/beta-Klotho or fgf19, -21, or -23 are associated with a number of human diseases, including autosomal dominant hypophosphatemic rickets, premature aging disorders, and diabetes. The Caenorhabditis elegans genome contains two paralogues of Klotho/beta-Klotho, klo-1, and klo-2. klo-1 is expressed in the C. elegans excretory canal, which is structurally and functionally paralogous to the vertebrate kidney. KLO-1 associates with EGL-15/FGFR, suggesting a role for KLO-1 in the fluid homeostasis phenotype described previously for egl-15/fgfr mutants. Altered levels of EGL-15/FGFR signaling lead to defects in excretory canal development and function in C. elegans. These results suggest an evolutionarily conserved function for the FGFR-Klotho complex in the development of excretory organs such as the mammalian kidney and the worm excretory canal. These results also suggest an evolutionarily conserved function for the FGFR-Klotho axis in metabolic regulation.

Keywords: Aging, C. elegans, Growth Factors, Kidney, Metabolic Regulation, Signal Transduction, FGF, Klotho, Endocrine

Introduction

FGFs and their receptor tyrosine kinases (FGFRs)2 comprise a signaling system that controls metazoan development, homeostasis, and adult pathobiology. FGF/FGFR signaling is traditionally associated with developmental processes ranging from cell division, migration, and differentiation to cell survival (1, 2). More recently, a subfamily of FGFs (FGF19, -21, and -23) has been associated with endocrine activities (3, 4). Unlike the classical FGFs, the endocrine FGFs have low affinity for heparan sulfate and do not require heparan sulfate proteoglycans for efficient FGFR interaction. Instead, the endocrine FGFs are present in the circulation and require type 1 transmembrane proteins Klotho and beta-Klotho, as obligatory co-factors to bind and activate their cognate FGFRs (for reviews, see Refs. 4 and 5).

Klotho was originally identified as an aging suppressor gene (6,8). Overexpression of Klotho extends life span and disruption of Klotho in mice leads to shorter life span with multiple disorders resembling human premature aging syndromes. Beta-Klotho (KLB) is a Klotho homologue and loss-of-function mutations in Klb lead to increased synthesis and excretion of bile acids in mice (9).

Given the wide distribution of FGFRs, Klotho and beta-Klotho are expressed in a more restricted manner and by facilitating the active FGF/FGFR complex formation, specify the target tissues for endocrine FGF action. FGF21 and -23 have selective preference for Klotho or beta-Klotho, further adding to the tissue specific action. Therefore, despite the fgfrs being ubiquitously expressed and the endocrine FGFs circulating in the body, the endocrine FGFs play distinct physiological roles. FGF19 utilizes either Klotho or beta-Klotho as a cofactor to regulate cholesterol/bile acid synthesis in the liver (10), FGF21 requires beta-Klotho to control glucose and lipid homeostasis in adipose tissue (11, 12), and FGF23 is dependent on Klotho to mediate phosphate and vitamin D metabolism in the kidney (13, 14).

The nematode C. elegans has a single orthologue of vertebrate fgfrs, egl-15, and two homologues of fgf ligands, egl-17 and let-756. EGL-15/FGFR has two differentially expressed isoforms EGL-15 (5A) and EGL-15 (5B), due to alternative splicing of the fifth exon. The intracellular signaling cascades activated by EGL-15 are relatively well characterized and share a high degree of conservation with mammalian FGFRs (15, 16). Loss of function in egl-15 (5B)/fgfr or in let-756/fgf lead to larval lethality, but the exact cause of this lethality is not known. EGL-15/FGFR signaling is negatively regulated by a receptor phosphatase, CLR-1 (17) and by N-glycosylation of the extracellular domain of EGL-15 (18). Removal of either of the negative controls results in excess EGL-15 signaling, leading to accumulation of fluid in the animal pseudocoelom and clear appearance of the animals (Clr phenotype).

The morphogen role of EGL-17/FGF and EGL-15(5A)/FGFR for the migration and differentiation of sex myoblasts is relatively well characterized (19,21). Whereas in mammals the morphogen and endocrine functions of FGFs have diverged, the role of EGL-15/FGFR signaling in fluid homeostasis and the suggested action of LET-756 as a paracrine factor (15), raise the intriguing possibility of parallel morphogen and endocrine functions for the C. elegans FGFs EGL-17 and LET-756. The C. elegans excretory cell is a large H-shaped cell with structural and functional parallels with the mammalian kidney (22, 23). The excretory cell is responsible for exchange of solutes and water to eliminate waste and to maintain osmotic homeostasis. We show that altered levels of EGL-15 signaling lead to defects in the excretory canal morphology. Excess EGL-15 activity in EGL-15 N-glycosylation mutants leads to defects in fluid homeostasis, with no effect on gross excretory canal morphology, suggesting defects in the canal function. We have identified the C. elegans orthologues of Klotho/beta-Klotho, klo-1 and klo-2, and show that parallel to Klotho/beta-Klotho regulating endocrine functions in mammals, klo-1 and klo-2 are expressed in the excretory canal, the intestine and the hypodermis, tissues which are responsible for ion homeostasis in C. elegans. klo-1 expression is regulated by EGL-15 signaling, EGL-15 associates with KLO-1 in vitro, and transgenic overexpression of klo-1 leads to defects in ion balance. Physiological stress causes developmental delay in mutants in KLO-1/KLO-2 or EGL-15 signaling. Taken together, these results suggest parallel endocrine and morphogen functions for the C. elegans FGFs and evolutionary conservation of FGFR/Klotho signaling in metabolic homeostasis.

EXPERIMENTAL PROCEDURES

Strains

C. elegans strains were maintained at 20 °C essentially as described (24) unless stated otherwise. Wild type strain used in this study is N2 var. Bristol. The following previously described mutant strains were used. LG I: CB3241; clr-1 (e1745ts). LG III: FF628; let-756 (s2613) unc-32 (e189), OH2638; dpy-17(e164) let-756(s2887) unc-32(e189) III; oyIs14 V; otEx1467 (let-756(+); pceh-22::GFP) (25). LG IV: MT4479; soc-2 (n1774). LG X: NH2693; egl-15 (n1456/szT1), TC341; egl-15 (n1456); jtEx79 (egl-15N401A,N407A,N433A, N440A; myo-3::gfp) (18). RB1549 carries an ok1862 deletion allele isolated by the C. elegans Gene Knock-out Consortium. We determined the breakpoints of the klo-2 (ok1862) allele and found it to be a 770-bp deletion and an adenosine insertion with genomic breakpoints 5′-ATTTCGACATGCCACTTGCGATA/TCTAGATCACACTCTTGCCGGCCTTA-3′. ok1862 leads to a premature stop codon and truncation of protein product after Ile129.

DNA Constructs and Transgenics

The p(l)klo-1::gfp reporter gene construct contains a 1378-bp fragment and the p(s)klo-1::gfp reporter gene construct contains a 238-bp fragment upstream of the ATG start codon of klo-1. The pklo-2::gfp reporter gene construct contains a 538-bp fragment upstream of the ATG start codon of klo-2. The DNA fragments were amplified by PCR (p(l)klo-1, 5′-gatcttccagcagtgaatattc-3′ and 5′-aaccgaacaagacatcgac-3′; p(s)klo-1, 5′-tcaaactctaattttgatattctg-3′ and 5′-aaccgaacaagacatcgac-3′; pklo-2, 5′-tcttcttttggatatacccttt-3′ and 5′-tgcggaacaacaaatgatcac-3′) and Gateway cloned into GFP/mCherry vectors based on pPD95.75. The p(l)klo-1::KLO-1 expression construct contains a 1300-bp fragment upstream of the ATG codon of klo-1 and the full-length klo-1 genomic fragment amplified by PCR (5′-gatcttccagcagtgaatattc-3′ and 5′-ctacaaaagattatgatgcttt-3′) and Gateway cloned into a vector containing the 3′-UTR sequence of unc-54. DNA microinjection was performed as described previously (26). Transgenic lines were created in wild type (N2) background at 30 ng/μl together with ptph-1::mCherry or pttx-3::RFP as co-injection marker. For each DNA microinjection, at least three independent transgenic lines were analyzed. p(l)klo-1::GFP was used to generate extrachromosomal arrays jtEx109-jtEx113, p(s)klo-1::GFP was used to make transgenic lines jtEx166-jtEx170, and pklo-2::GFP was used to generate extrachromosomal arrays jtEx129-jtEx132. jtEx163-jtEx165 contain p(l)klo-1::KLO-1 expression construct together with ptph-1::mCherry, and jtEx166-jtEx169 contain p(l)klo::KLO-1 expression construct together with p(s)klo-1::GFP.

Protein Purification and Western Blotting

C. elegans were ground in liquid nitrogen, and frozen worm powder was solubilized in a buffer containing 1% Igepal (Nonidet P40; SigmaAldrich) in 50 mm Tris-HCl, pH 7.5, 0.15 m NaCl. 1 μm phenylmethylsulfonyl fluoride, 2 mg/ml aprotinin (Sigma), and 1× Protease Inhibitor Cocktail (Roche Diagnostics) were added to prevent proteolysis. Protein lysates were cleared by centrifugation at 10,000 × g for 30 min at +4 °C. Proteins were immunoprecipitated with rat monoclonal anti-Klotho antibody (R&D Systems) or rabbit polyclonal anti-EGL-15 antibody, Crackle (a generous gift from professor Michael Stern). Immunoprecipitates were captured using protein A- or protein G-agarose beads (SigmaAldrich), samples were separated on a 10% SDS-PAGE and transferred into an Immobilon-P PVDF membrane (Millipore). Proteins were detected with anti-Klotho or Crackle antibodies, followed by anti-rabbit or anti-mouse HRP-conjugated secondary antibodies (GE Healthcare) and ECL Chemilumenescence Detection kit (Biological Industries, Beit Haemek, Israel).

Life Span and Physiological Stress Assays

Life span assays were conducted as described previously (27). Age refers to days after adulthood, and p values were calculated using the Log-rank (Mantel-Cox) method. Response to physiological stress under 0 mm Mg2+ and 0 mm Ca2+ conditions was assayed essentially as described previously (28) with the following modifications. Eggs from each strain were transferred to control, 0 mm Mg2+ or 0 mm Ca2+ plates (50 eggs/plate) and grown at 23 °C in parallel, and the number of adults was counted every 12 h.

Microscopy

Fluorescent and differential interference contrast images were acquired using Zeiss AxioCam MRm camera mounted on Zeiss Axioskop2 microscope equipped with ×10, ×20, ×40, and ×63 epifluorescence and differential interference contrast optics. Images were captured using Axiovision and further cropped and scaled using Adobe Photoshop CS4.

RESULTS

C50F7.10 and E02H9.5 Encode C. elegans Klotho/Beta-Klotho Homologues klo-1 and klo-2

A Blast search of the C. elegans database identifies the sequences C50F7.10 and E02H9.5 as the homologues of vertebrate Klotho/beta-Klotho, which we have named klo-1 and klo-2. The vertebrate Klotho/beta-Klotho contain ~1000 amino acids and consist of a signal peptide, two Klotho domains, KL1 and KL2, which share ~28% sequence identity, a transmembrane domain and a short cytoplasmic domain (29, 30) (Fig. 1B). The predicted C. elegans KLO-1 contains 479 amino acids and ClustalW analysis shows 33–35% sequence identity to vertebrate Klothos (Fig. 1D) and 29–30% identity to beta-Klothos (supplemental Fig. S1). The predicted KLO-2 contains 475 amino acids and bears 34–35 and 33–34% sequence identity to vertebrate Klothos and beta-Klothos, respectively (Fig. 1 and supplemental Fig. S1). KLO-1 and KLO-2 contain ~33–35% sequence identity to the first vertebrate Klotho domain (KL1) and 18–24% sequence identity to vertebrate KL2 domains. Klotho orthologues are present in other Caenorhabditis species (Caenorhabditis brenneri, Caenorhabditis brigssae, and Caenorhabditis remanei) and in Drosophila. The nematode and fruit fly Klotho genes encode proteins with a single KL domain with no predicted transmembrane domain, and phylogenetic analysis suggests that the nematode Klotho genes may represent ancestral forms of the vertebrate Klothos (Fig. 1E). Both human and mouse Klotho genes are alternatively spliced to produce a shorter, secreted isoform (29, 30), which resembles the nematode and fruit fly Klotho proteins containing only one KL domain. It is plausible that the C. elegans KLO-1 and KLO-2 are secreted and may mediate their function cell non-autonomously. The predicted KLO-1 protein lacks a putative secretion signal. We analyzed the 5′-ends of klo-1 mRNA using RT-PCR and confirmed that the predicted 5′-end of the klo-1 cDNA is correct (data not shown). From the protein sequence, it is thus not possible to predict KLO-1 protein localization.

FIGURE 1.
Molecular characterization of klo-1 and klo-2, which encode the C. elegans Klotho homologues. A, schematic structure of klo-1 (C50F7.10) and klo-2 genes (E02H9.5). Gray boxes, exons; black lines, mRNA-splicing pattern. The klo-2 deletion ok1862 is underlined ...

klo-1 and klo-2 Are Expressed in Excretory System

klo-1 and klo-2 expression was analyzed using transgenic animals carrying transcriptional GFP reporters driven by sequences upstream of the first exon of either gene. pklo-1::GFP expression is first observed in the developing intestine in embryos at ~270 min after first cell cleavage (Fig. 2C). pklo-1::GFP expression in the developing intestine persist throughout embryonic development. At the first larval stage, pklo-1::GFP expression is seen in the excretory canal where the expression continues in adults in all transgenic lines analyzed (Fig. 2, A, B, and F). pklo-2::GFP expression is similarly first detected in the developing intestine at ~270 min after first cell cleavage (Fig. 2E), and the expression of klo-2::GFP in the intestine persists in adults in all five transgenic lines analyzed (Fig. 2F). pklo-2::GFP expression is also observed in the hypodermis (epidermis) in one of the transgenic lines analyzed (Fig. 2, D and F). These findings suggest that the expression of klo-1 and klo-2 partially overlap. Both klo-1 and klo-2 are expressed in the intestine, klo-1 is expressed in the excretory canal, and klo-2 is expressed in the hypodermis. Together, these tissues comprise the C. elegans organs that are involved in osmoregulation and uptake and secretion of metabolites. These results also suggest that the function of Klotho and beta-Klotho in regulation of ion balance is evolutionarily conserved from nematodes to mammals.

FIGURE 2.
Expression of pklo-1::GFP and pklo-2::GFP reporter genes. A and B, pklo-1::GFP is expressed in the excretory canal both in larvae and in adults. A, inset, higher magnification showing pklo-1::GFP expression in the excretory canals. B, pklo-1::GFP expression ...

egl-15/fgfr Signaling Is Required for klo-1 Expression in Excretory Canal

Vertebrate Klotho and beta-Klotho function as obligatory co-factors for endocrine FGFs to bind and activate their cognate FGF receptors. C. elegans contains a single homologue of vertebrate fgfrs, egl-15, and two homologues of fgfs, egl-17 and let-756. Loss-of-function alleles of both egl-15/fgfr and let-756/fgf are lethal at the first larval stage (L1), but the exact nature of this lethality remains unknown (for reviews, see Refs. 15 and 31). Hypomorphic alleles of egl-15 and let-756 are scrawny (scr). Excess EGL-15 activity leads to defects in osmoregulation and fluid accumulation within the animals, resulting in a clear (Clr) phenotype (17, 18). The C. elegans excretory canal is formed from a single excretory cell born midway through embryogenesis (for a review, see Ref. 32). The excretory cell undergoes morphogenesis to form an “H”-shaped tubular cell consisting of two excretory canals that run laterally on either side of the animal. At hatching, the posterior canals have reached about half of the length of the animal and continue to extend throughout the first larval stage. By the end of the first larval stage, the excretory canal ends have reached the tail of the animal, and after that, the canals grow as the worms grow in size. Laser ablation of either the excretory cell or the canal-associated neurons, which are thought to regulate the excretory system, leads initially to fluid accumulation and later to lethality demonstrating that the excretory canal is essential for viability (23). C. elegans survives without a functional excretory system until the excretory canals have fully developed in late first larval stage. Due to the tubular form and role in osmoregulation, the excretory canal is structurally and functionally equivalent to the vertebrate kidney. Given the plausible link between EGL-15/FGFR, KLO-1/Klotho, and regulation of fluid homeostasis, transgenic pklo-1::GFP expression in the excretory canals was used to assess canal morphology in mutants that lack EGL-15 signaling. egl-15 (n1456) is a loss-of-function (lf) allele and as homozygous leads to lethality at first larval stage (L1). egl-15 (lf) was maintained as heterozygous and L1 progeny were selected for analysis of pklo-1::GFP expression based on the scrawny phenotype of egl-15 (lf) homozygotes. Of the egl-15 (lf) progeny analyzed at late L1 stage 83% (n = 52) lacked expression of pklo-1::GFP despite carrying the co-injection marker present in the transgenic array (Fig. 3, D and E). This represents a statistically significant difference when compared with animals analyzed at later developmental stages (from L2 to young adults), and thus representing egl-15 (lf)/+ heterozygotes, of which only 30% (n = 40) of the progeny did not show pklo-1::GFP expression when the co-injection marker was present (Fig. 3; p < 0.001 by chi-square test). Expression of pklo-1::GFP was also absent in the gut of egl-15 (lf) mutants. These findings suggest that klo-1 is a EGL-15-responsive gene.

FIGURE 3.
klo-1 reporter expression is absent in mutants that lack EGL-15/LET-756 signaling. Shown are differential interference contrast (A and C) and epifluorescence images (B and D) of egl-15 (+); pklo-1::GFP control animals (A and B) and egl-15 (n1456); pklo-1 ...

Similarly, pklo-1::GFP expression in the excretory cell was absent in null mutants of let-756/fgf. pklo-1::GFP expression in the excretory canal was absent in 93% of the scrawny L1 progeny (n = 69) of let-756 (s2887) mutants (Fig. 3E). Expression of pklo-1::GFP was also absent in the gut. Reducing the level of LET-756 in a hypomorphic allele of let-756 (s2631) had no effect on pklo-1::GFP expression in the excretory canals (n = 26; Fig. 3E). The s2613 allele is a C-to-T transition leading to the replacement of arginine 318 by a stop codon (33). This truncates the LET-756/FGF protein by a quarter of its C terminus, leaving the core FGF domain intact. It is plausible that the presence of the core FGF domain of LET-756 in the hypomorphs is sufficient for EGL-15 signaling to prompt pklo-1::GFP expression. Heterozygous egl-15 (lf)/+ mutants also express pklo-1::GFP further, suggesting that klo-1 expression is sensitive to levels of EGL-15/LET-756 signaling. Taken together, these results suggest that klo-1 expression is responsive to LET-756/EGL-15 signaling.

KLO-1 Associates with EGL-15/FGFR

To establish whether KLO-1 and EGL-15 interact, total protein lysates of wild type C. elegans were immunoprecipitated with monoclonal Klotho or polyclonal EGL-15 antibodies. Polyclonal EGL-15 antibody enriched both EGL-15 and KLO-1 from total C. elegans protein lysates, as detected by Western blotting using anti-Klotho and anti-EGL-15 (Fig. 4). Conversely, monoclonal anti-Klotho enriched both KLO-1 and EGL-15 from total C. elegans protein lysates. These results demonstrate that KLO-1 associates with EGL-15. KLO-1 migrated on SDS-PAGE corresponding to molecular mass of 110 kDa, which is greater than the theoretical mass of 50 kDa. A number of causes may lead to altered mobility of proteins on SDS-PAGE, which for KLO-1, include the possibility that its two potential N-glycosylation sites, which are conserved in KLO-2 (Fig. 1D), are glycosylated and the formation of SDS-resistant dimers.

FIGURE 4.
KLO-1 associates with EGL-15/FGFR. Total protein lysates and immunoprecipitates of wild type C. elegans proteins with either anti-EGL-15 or anti-Klotho antibodies were blotted with either anti-Klotho or anti-EGL-15 antibodies. Monoclonal anti-Klotho antibodies ...

Levels of EGL-15/FGFR Activity Critically Control Excretory Canal Development

Excess EGL-15 activity leads to accumulation of fluid within the animal body cavity (17, 18), suggesting defects in the excretory/secretory functions. Mutants with altered levels of EGL-15 activity were used to assess for morphological defects in excretory canal development. All strains were analyzed between larval stages L2 and L4 to ensure the canals should have been normally developed (by late L1) and to overcome the fact that the posterior ends of the excretory canals can sometimes “snap” in adult worms as they move, leading to shortened excretory canals. CLR-1 is a phosphatase that was originally identified as a negative regulator of EGL-15 activity, defects in which lead to the Clr phenotype (17). All current data point to CLR-1 being specific to EGL-15. A temperature-sensitive allele of clr-1, e1745ts, was grown at a nonpermissive temperature for 24 h, and the mutant animals were analyzed for excretory canal morphology using the pklo-1::GFP marker. In control animals expressing the pklo-1::GFP marker in an otherwise wild type background, 94% of the excretory canals extended the entire length of the animal (n = 49) (Figs. 2A and and55H). In 53% of clr-1 (e1745ts) animals (n = 47) grown at a nonpermissive temperature for 24 h, the excretory canals stopped prematurely and did not extend the full length of the animal (Fig. 5, B and C). Furthermore, in 22% of clr-1 animals, the canals contained enlarged cysts. These findings suggest that the absence of negative regulation of EGL-15 signaling by CLR-1 phosphatase leads to defects in excretory canal extension contributing to the fluid accumulation in these mutants.

FIGURE 5.
Abnormal levels of EGL-15/FGFR signaling lead to defects in excretory canal development. A, schematic drawing of the H-shaped excretory canals (green). B and C, in temperature-sensitive clr-1 mutants grown at nonpermissive temperature, the excretory canals ...

Genetic removal of specific N-glycosylation sites from the extracellular domain of EGL-15 also leads to excess EGL-15 activity and the Clr phenotype, suggesting that N-glycans negatively regulate EGL-15 (18). egl-15 (N401A,N407A,N433A, N440A) mutants, with four putative N-glycosylation sites abolished, develop the Clr phenotype. However, analysis of the excretory canals in these mutants showed that the excretory canals extended the entire length of the animal (Fig. 5, F and G). These results suggest that the excess EGL-15 activity due to lack of N-glycans does not affect the extension and cross-morphology of the canals. However, the fact that these animals display the Clr phenotype suggests that excretory function is disrupted in these mutants. N-glycans of the extracellular domain of EGL-15 may regulate EGL-15 interactions with molecules involved in osmoregulation such as ion channels, and removal of these glycans may hinder these interactions and thus ion channel function. Removal of N-glycans from IgD3 of EGL-15 does not, however, abolish association of EGL-15 with KLO-1 (see supplemental Fig. S2).

The morphology of the excretory canals was also analyzed in mutants with reduced levels of EGL-15/FGFR signaling. soc-2 is an EGL-15 downstream signaling component, hypomorphic mutations of which suppress the clear phenotype of hyperactive egl-15 mutants (18, 34). In soc-2 (n1774) mutants, the excretory canals fail to extend the entire length of 52% of the animals (n = 31) and stop short. Furthermore, in soc-2 (n1774) mutants, the canals frequently contain enlarged cysts (Fig. 5D, inset). The soc-2 short stop phenotype can be partially suppressed to 20% (n = 45) by transgenic overexpression of klo-1 (Fig. 5H), suggesting that increasing the level of KLO-1 can overcome reduction in EGL-15 downstream signaling. It is plausible that KLO-1 facilitates EGL-15 signaling complex formation. Reducing the levels of LET-756/FGF in the hypomorphic mutant s2613, did not lead to defects in excretory canal extension (n = 20), suggesting that the core domain of LET-756 (see above) is sufficient for excretory canal extension. Taken together, these results indicate that the excretory canal development is sensitive to levels of EGL-15/FGFR signaling, EGL-15 acts in concert with KLO-1 to regulate excretory canal development and disturbances in EGL-15/KLO-1 signaling lead to defects in fluid homeostasis.

klo-1 Gain-of-function Leads to Molting Defects and Accumulation of Fluid-filled Cysts

To obtain further insight into KLO-1 function, klo-1 gain-of-function (referred as klo-1(gf) from here on) animals were obtained by transgenic expression of the klo-1 promoter driving genomic klo-1 expression in wild type C. elegans. klo-1 (gf) lead to molting defects (Fig. 6, A–B). klo-1 (gf) also lead to defects in gonad development (Fig. 6, A–B). In klo-1 (gf) animals, 19% of the anterior gonad leader cells or distal tip cells (n = 42) failed to execute ventral to dorsal reorientation (phase 2) resulting in overextension of the anterior gonad arms (Fig. 6B).

FIGURE 6.
klo-1 gain of function leads to defects in molting, gonad development, and fluid homeostasis. A, C, and E, wild type (N2) controls. B, D, and F, klo-1 (gf) mutants. A and B, klo-1 (gf) leads to molting defects (arrows) where the cuticle becomes detached ...

The most prominent phenotype of the klo-1 (gf) was accumulation of fluid-filled cysts under the hypodermis (Fig. 6, D and F). These cysts appeared along the entire length of the animal and varied in size. This phenotype is reminiscent of a weak Clr phenotype. Although the Clr phenotype of the klo-1 (gf) animals is weaker than that observed in strong clr-1 mutants or in hyperactive egl-15 mutants, the similarity in the phenotype suggest that consistent with vertebrate Klotho functionally interacting with FGF receptors, KLO-1 interacts with EGL-15/FGFR to regulate excretory canal development and function.

Abnormal Levels of EGL-15/FGFR and KLO-1/Klotho Signaling Sensitize to Physiological Stress

In mice, overexpression of Klotho extends life span and disruption of Klotho leads to shorter life span with multiple disorders resembling human premature aging syndromes (6, 7). Analysis of klo-1 (gf) animals in standard laboratory conditions showed significant differences in survival curves, as compared with wild type controls (Fig. 7A; p < 0.05 (*) significance; Log-rank test) with a median survival of 21 days for klo-1 (gf) (n = 56) and 17 days for wild type controls (n = 48). These results suggest that in addition to the evolutionary conservation of KLO-1 function in ion homeostasis, the life span-enhancing effects of KLO-1/Klotho are also evolutionarily conserved.

FIGURE 7.
Altered levels of EGL-15/KLO-1 signaling sensitize to physiological stress. A, under standard laboratory culture conditions on nematode growth media (NGM) agar, klo-1 (gf) leads to extension of life span as compared with siblings that do not express the ...

Mutants with abnormal levels of either EGL-15/FGFR or KLO-1/KLO-2 signaling were subjected to physiological stress by altering the ion strength of their environment. Wild type C. elegans tolerated changes in their microenvironment well and did not show a significant delay in reaching adulthood when grown in limited sources of Ca2+ or Mg2+ ions. In contrast, egl-15 (N401A,N407A,N433A,N440A) N-glycosylation mutants showed delay in development when subjected to physiological stress. egl-15 (N401A,N407A,N433A,N440A) mutants show ~55% embryonic and larval lethality (data not shown) and delay in development to adulthood even when grown under normal laboratory conditions. As some of the egl-15 (N401A,N407A,N433A,N440A) mutants become very severely clear, it is difficult to accurately determine their developmental stage. However, those egl-15 (N401A,N407A,N433A,N440A) mutants that do not develop a severe Clr phenotype have delayed development, as compared with wild type worms even under normal culture conditions (Fig. 7B). This delay becomes more accentuated when the mutants are subjected to physiological stress (Fig. 7, B and C). At 60 h, 98% of wild type worms grown on standard or ion-depleted environment have reached adulthood, as compared with 50% or only 25% of egl-15 (N401A,N407A,N433A,N440A) mutants, when grown on standard or ion-depleted environment, respectively. Similarly, klo-1 (gf) mutants displayed slight delay in development, as compared with wild type animals when grown on standard conditions, and this delay becomes more emphasized when the animals are grown under physiological stress (Fig. 7, B and C).

ok1862 Is a Deletion Allele of klo-2

We have sequenced the deletion breakpoints (see “Experimental Procedures”) and established that the ok1862 deletion leads to a premature stop codon resulting in truncation of the KLO-2 protein after Ile129 (Fig. 1). The ok1862 is thus considered as a null allele of klo-2. ok1862 mutants have superficially wild type morphology and normal fertility (data not shown). However, similarly to egl-15 N-glycosylation and klo-1 (gf) mutants, the ok1862 mutants show delayed development under physiological stress as compared with wild type (Fig. 7, B and C).

DISCUSSION

We have shown that the role of FGFs as endocrine regulators of physiological functions is evolutionarily conserved from nematodes to mammals. The C. elegans FGF signaling system with two FGF ligands, LET-756 and EGL-17, and one FGF receptor, EGL-15, has both morphogen and endocrine functions. The role of Klotho/beta-Klotho in endocrine functions of FGFR is evolutionarily conserved.

Given the abundant expression of FGF receptors in vertebrates, Klotho and beta-Klotho expression is more restricted and is thought to specify the tissues of endocrine FGF action. We found C. elegans klo-1 and klo-2 expression predominantly in the intestine, the excretory canal, and the hypodermis, tissues that are responsible for regulation of metabolic homeostasis in the worm. We show that klo-1 expression in the excretory canal is responsive to LET-756/EGL-15 signaling. We show that KLO-1 and EGL-15 associate biochemically in pulldown assays. Given the previously demonstrated role of EGL-15 signaling in control of fluid homeostasis (17, 18), our results strongly suggest that KLO-1 and EGL-15 associate in vivo and that the role of Klotho/beta-Klotho in defining the endocrine actions of FGFs is thus evolutionarily conserved.

The C. elegans excretory canal is formed from a single, large, H-shaped excretory cell that sends processes anteriorly and posteriorly from the cell body. The excretory cell together with the duct cell and the pore cell confine the excretory organ functionally and structurally paralogous to the mammalian kidney (22). Abolishing any of these cells by laser ablation causes the animal to swell with fluid and die (23). The lack of klo-1 expression in the excretory canals of egl-15 (lf) or let-756 (lf) animals and the aberrant morphology of the canals in clr-1 mutants, which have hyperactive EGL-15 signaling, reveal a role for FGF signaling in the development of the excretory canal. The morphogenesis of the excretory canals is completed by the end of the first larval stage, after which the canals grow in size as the worms grow. C. elegans thus survives without functional excretory canals until late L1 stage. Both egl-15 (lf) and let-756 (lf) mutants die at late L1 stage for reasons that have so far been unknown. Our results strongly suggest that the lack of functional excretory canals in these animals is the underlying cause for lethality.

In vertebrates, FGF21 selectively requires beta-Klotho for signaling as a major metabolic regulator of glucose and lipid metabolism and obesity. Fgf23 and Klotho loss-of-function mice display identical aging like phenotypes with defects in phosphate, Ca2+ and vitamin D homeostasis (6, 35). In C. elegans, overexpression of klo-1 also led to statistically significant enhancement of life span as compared with wild type siblings. The effect on life span was prominent throughout adulthood, and klo-1 (gf) animals lived longer than wild type siblings. This was somewhat surprising, considering the molting defect and accumulation of fluid filled cysts within the klo-1 (gf) animals. Given the current lack of a klo-1 loss-of-function allele as a genetic tool, we cannot at this stage comprehensively address the role of KLO-1 in life span extension.

Removal of negative regulation of EGL-15 signaling by inactivating mutations in CLR-1 phosphatase leads to a failure of the excretory canals to extend fully and accumulation of fluid inside the animals. Similarly, mutations in soc-2, an intracellular downstream regulator of EGL-15, lead to shortened excretory canals and enlarged cysts within the canal ends. These results suggest that the levels of intracellular EGL-15 signaling are important for normal canal development and extension. Both too much and too little of EGL-15 signaling lead to abnormal excretory canal extension. We have previously shown that N-glycosylation of the extracellular domain of EGL-15 negatively regulates receptor activity and removal of specific N-glycans of EGL-15 leads to accumulation of fluid and the clear phenotype (18). Intriguingly, we could not detect any cross morphological defects in the excretory canals of EGL-15 N-glycosylation mutants, despite defects in osmoregulation. These results suggest a different mechanism by which N-glycans regulate EGL-15 signaling in fluid homeostasis as compared with negative regulation of intracellular phosphorylation of EGL-15 by CLR-1 phosphatase. N-glycosylation of EGL-15 may mediate extracellular/membrane interactions of EGL-15/FGFR with other membrane proteins, such as ion channels, involved in osmoregulation. Consistent with this suggestion, the EGL-15 N-glycosylation mutants are sensitive to physiological stress, as shown by delayed development under ion depletion in their environment. Similarly, klo-1 (gf) mutants show slightly delayed development under physiological stress. Klotho has been shown to stimulate transient receptor potential ion channel (TRPV5) by increasing the channel retention time on plasma membrane in murine and human cells in vitro (36, 37). TRPV5 is a Ca2+ channel involved in renal Ca2+ handling, and mutations in TRPV5 cause disturbances in Ca2+ homeostasis similar to those seen in Klotho-deficient in mice. It is thus plausible that EGL-15/FGFR forms a complex with an ion channel to regulate fluid balance, and KLO-1/KLO-2 may facilitate this complex formation. Klotho has also been suggested to possess glycosidase activity (6, 38) and to modulate glycans on TRPV5 (36, 37). This raises the possibility that C. elegans KLO-1 may modulate N-glycans of EGL-15 or alternatively that N-glycans of EGL-15 mediate interaction with KLO-1. Unlike the vertebrate Klotho proteins, KLO-1 and KLO-2 lack a transmembrane domain, suggesting they may exist as soluble or membrane-associated proteins. KLO-1/KLO-2 may thus function either as co-factors to facilitate ligand binding to EGL-15/FGFR or as hormone-like ligands for EGL-15. Vertebrate Klothos retain the soluble forms because they are detected in serum and cerebrospinal fluid (39) and in the cell supernatant in vitro (36), presumably due to shedding following cleavage by matrix metalloproteinases (40, 41) or translation of alternatively spliced mRNA in which the transmembrane and intracellular domains are lost (29, 30). Based on current data, the membrane-anchored and the shed forms of the vertebrate Klothos mediate different physiological responses (42).

In conclusion, we have shown that compared with mammals, in which the morphogen and endocrine functions of FGFs have diverged, in C. elegans, with reduced complexity of the FGF signaling system, the morphogen and endocrine functions of FGF signaling are retained in parallel. EGL-15/FGFR signaling regulates both the development and the function of the excretory system. We have identified the C. elegans Klotho/beta-Klotho homologues, klo-1 and klo-2, and show that klo-1 and klo-2 are specifically expressed in organs involved in osmoregulation in C. elegans. EGL-15 regulates klo-1 expression and associates biochemically with KLO-1. Abnormal levels of EGL-15 or KLO-1 lead to defects in osmoregulation and sensitivity to physiological stress. Finally, our results thus demonstrate that the role of Klotho/beta-Klotho in endocrine functions of FGFR is evolutionarily conserved nematodes to mammals.

Supplementary Material

Supplemental Data:

Acknowledgment

We thank professor Michael Stern for kindly providing the polyclonal anti-EGL-15 antibody, Crackle.

*Some strains used in this study were obtained from the Caenorhabditis Genetics Center, which is supported by the National Institutes of Health National Center for Research Resources, and by the C. elegans Knock-out Consortium. This work was supported by a European Union Marie Curie Early Stage Training Programme (to U. M. P.), by the North West Cancer Research Fund and the Cancer and Polio Research Fund (to D. G. F.), and by the Medical Research Council (to T. K. K.).

An external file that holds a picture, illustration, etc.
Object name is sbox.jpgThe on-line version of this article (available at http://www.jbc.org) contains supplemental Figs. S1 and S2.

2The abbreviation used is:

FGFR
FGF receptor.

REFERENCES

1. Eswarakumar V. P., Lax I., Schlessinger J. (2005) Cytokine Growth Factor Rev. 16, 139–149 [PubMed]
2. Ornitz D. M., Itoh N. (2001) Genome Biol. 2, REVIEWS3005 [PMC free article] [PubMed]
3. Kharitonenkov A. (2009) Curr. Opin. Pharmacol. 9, 805–810 [PubMed]
4. Razzaque M. S., Lanske B. (2007) J. Endocrinol. 194, 1–10 [PMC free article] [PubMed]
5. Kuro-o M. (2006) Curr. Opin. Nephrol. Hypertens. 15, 437–441 [PubMed]
6. Kuro-o M., Matsumura Y., Aizawa H., Kawaguchi H., Suga T., Utsugi T., Ohyama Y., Kurabayashi M., Kaname T., Kume E., Iwasaki H., Iida A., Shiraki-Iida T., Nishikawa S., Nagai R., Nabeshima Y. I. (1997) Nature 390, 45–51 [PubMed]
7. Kurosu H., Yamamoto M., Clark J. D., Pastor J. V., Nandi A., Gurnani P., McGuinness O. P., Chikuda H., Yamaguchi M., Kawaguchi H., Shimomura I., Takayama Y., Herz J., Kahn C. R., Rosenblatt K. P., Kuro-o M. (2005) Science 309, 1829–1833 [PMC free article] [PubMed]
8. Tsujikawa H., Kurotaki Y., Fujimori T., Fukuda K., Nabeshima Y. (2003) Mol. Endocrinol. 17, 2393–2403 [PubMed]
9. Ito S., Fujimori T., Furuya A., Satoh J., Nabeshima Y. (2005) J. Clin. Invest. 115, 2202–2208 [PMC free article] [PubMed]
10. Lin B. C., Wang M., Blackmore C., Desnoyers L. R. (2007) J. Biol. Chem. 282, 27277–27284 [PubMed]
11. Kharitonenkov A., Dunbar J. D., Bina H. A., Bright S., Moyers J. S., Zhang C., Ding L., Micanovic R., Mehrbod S. F., Knierman M. D., Hale J. E., Coskun T., Shanafelt A. B. (2008) J. Cell. Physiol. 215, 1–7 [PubMed]
12. Ogawa Y., Kurosu H., Yamamoto M., Nandi A., Rosenblatt K. P., Goetz R., Eliseenkova A. V., Mohammadi M., Kuro-o M. (2007) Proc. Natl. Acad. Sci. U.S.A. 104, 7432–7437 [PubMed]
13. Kurosu H., Ogawa Y., Miyoshi M., Yamamoto M., Nandi A., Rosenblatt K. P., Baum M. G., Schiavi S., Hu M. C., Moe O. W., Kuro-o M. (2006) J. Biol. Chem. 281, 6120–6123 [PMC free article] [PubMed]
14. Urakawa I., Yamazaki Y., Shimada T., Iijima K., Hasegawa H., Okawa K., Fujita T., Fukumoto S., Yamashita T. (2006) Nature 444, 770–774 [PubMed]
15. Birnbaum D., Popovici C., Roubin R. (2005) Dev. Dyn. 232, 247–255 [PubMed]
16. Polanska U. M., Fernig D. G., Kinnunen T. (2009) Dev Dyn 238, 277–293 [PubMed]
17. Kokel M., Borland C. Z., DeLong L., Horvitz H. R., Stern M. J. (1998) Genes Dev. 12, 1425–1437 [PubMed]
18. Polanska U. M., Duchesne L., Harries J. C., Fernig D. G., Kinnunen T. K. (2009) J. Biol. Chem. 284, 33030–33039 [PMC free article] [PubMed]
19. Burdine R. D., Chen E. B., Kwok S. F., Stern M. J. (1997) Proc. Natl. Acad. Sci. U.S.A. 94, 2433–2437 [PubMed]
20. DeVore D. L., Horvitz H. R., Stern M. J. (1995) Cell 83, 611–620 [PubMed]
21. Sasson I. E., Stern M. J. (2004) Development 131, 5381–5392 [PubMed]
22. Nelson F. K., Albert P. S., Riddle D. L. (1983) J. Ultrastruct. Res. 82, 156–171 [PubMed]
23. Nelson F. K., Riddle D. L. (1984) J. Exp. Zool. 231, 45–56 [PubMed]
24. Brenner S. (1974) Genetics 77, 71–94 [PubMed]
25. Bülow H. E., Boulin T., Hobert O. (2004) Neuron 42, 367–374 [PubMed]
26. Mello C. C., Kramer J. M., Stinchcomb D., Ambros V. (1991) EMBO J. 10, 3959–3970 [PubMed]
27. Apfeld J., Kenyon C. (1999) Nature 402, 804–809 [PubMed]
28. Teramoto T., Lambie E. J., Iwasaki K. (2005) Cell Metab. 1, 343–354 [PMC free article] [PubMed]
29. Matsumura Y., Aizawa H., Shiraki-Iida T., Nagai R., Kuro-o M., Nabeshima Y. (1998) Biochem. Biophys. Res. Commun. 242, 626–630 [PubMed]
30. Shiraki-Iida T., Aizawa H., Matsumura Y., Sekine S., Iida A., Anazawa H., Nagai R., Kuro-o M., Nabeshima Y. (1998) FEBS Lett. 424, 6–10 [PubMed]
31. Borland C. Z., Schutzman J. L., Stern M. J. (2001) Bioessays 23, 1120–1130 [PubMed]
32. Buechner M. (2002) Trends Cell Biol. 12, 479–484 [PubMed]
33. Roubin R., Naert K., Popovici C., Vatcher G., Coulier F., Thierry-Mieg J., Pontarotti P., Birnbaum D., Baillie D., Thierry-Mieg D. (1999) Oncogene 18, 6741–6747 [PubMed]
34. Selfors L. M., Schutzman J. L., Borland C. Z., Stern M. J. (1998) Proc. Natl. Acad. Sci. U.S.A. 95, 6903–6908 [PubMed]
35. Shimada T., Kakitani M., Yamazaki Y., Hasegawa H., Takeuchi Y., Fujita T., Fukumoto S., Tomizuka K., Yamashita T. (2004) J. Clin. Invest. 113, 561–568 [PMC free article] [PubMed]
36. Chang Q., Hoefs S., van der Kemp A. W., Topala C. N., Bindels R. J., Hoenderop J. G. (2005) Science 310, 490–493 [PubMed]
37. Cha S. K., Ortega B., Kurosu H., Rosenblatt K. P., Kuro-O. M., Huang C. L. (2008) Proc. Natl. Acad. Sci. U.S.A. 105, 9805–9810 [PubMed]
38. Tohyama O., Imura A., Iwano A., Freund J. N., Henrissat B., Fujimori T., Nabeshima Y. (2004) J. Biol. Chem. 279, 9777–9784 [PubMed]
39. Imura A., Iwano A., Tohyama O., Tsuji Y., Nozaki K., Hashimoto N., Fujimori T., Nabeshima Y. (2004) FEBS Lett. 565, 143–147 [PubMed]
40. Bloch L., Sineshchekova O., Reichenbach D., Reiss K., Saftig P., Kuro-o M., Kaether C. (2009) FEBS Lett. 583, 3221–3224 [PMC free article] [PubMed]
41. Chen C. D., Podvin S., Gillespie E., Leeman S. E., Abraham C. R. (2007) Proc. Natl. Acad. Sci. U.S.A. 104, 19796–19801 [PubMed]
42. Kuro-o M. (2010) Pflugers Arch. 459, 333–343 [PubMed]

Articles from The Journal of Biological Chemistry are provided here courtesy of American Society for Biochemistry and Molecular Biology